NCT04200248View on ClinicalTrials.gov

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

November 19, 2021

Study Completion Date

December 22, 2021

Conditions

Exudative Age-related Macular Degeneration

Interventions

DRUG

RBM-007 Injectable Solution

DRUG

Aflibercept

EYLEA® (aflibercept) Injection, for Intravitreal Use

DRUG

Sham

Sham intravitreal injection

Trial Locations (8)

30060

Georgia Retina, P.C., Marietta

33067

Advanced Research, LLC, Coral Springs

46290

Raj K. Maturi, M.D., P.C., Indianapolis

78240

Medical Center Ophthalmology Associates, San Antonio

78503

Valley Retina Institute, PA, McAllen

85053

Retinal Research Institute, LLC, Phoenix

94704

Bay Area Retina Associates, Walnut Creek

95841

Retinal Consultants Medical Group, Sacramento

All Listed Sponsors

lead

Ribomic USA Inc

INDUSTRY

NCT04200248 - A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter